Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Moupali Das

Showing results (31-40 of 61) with videos related to

Pageof 7
Sort By:
Prevention Science : the Official Journal of the Society for Prevention Research|February 16, 2013
A roadmap for adapting an evidence-based HIV prevention intervention: personal cognitive counseling (PCC) for episodic substance-using men who have sex with menKelly R Knight, Moupali Das, Erin DeMicco, et al.
Clinical Pharmacology and Therapeutics|December 23, 2022
Facilitating Next-Generation Pre-Exposure Prophylaxis Clinical Trials Using HIV Recent Infection Assays: A Consensus Statement from the Forum HIV Prevention Trial Design ProjectNeil Parkin, Fei Gao, Eduard Grebe, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|March 11, 2017
Brief Report: Randomized, Double-Blind Comparison of Tenofovir Alafenamide (TAF) vs Tenofovir Disoproxil Fumarate (TDF), Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine (E/C/F) for Initial HIV-1 Treatment: Week 144 ResultsJosé R Arribas, Melanie Thompson, Paul E Sax, et al.
Transgender Health|February 5, 2024
Gender Affirming Hormones Do Not Affect the Exposure and Efficacy of F/TDF or F/TAF for HIV Preexposure Prophylaxis: A Subgroup Analysis from the DISCOVER TrialMichelle S Cespedes, Moupali Das, Jenna Yager, et al.
Ebiomedicine|October 16, 2016
Equivalent Decline in Inflammation Markers with Tenofovir Disoproxil Fumarate vs. Tenofovir AlafenamideNicholas T Funderburg, Grace A McComsey, Manjusha Kulkarni, et al.
HIV Research & Clinical Practice|July 16, 2019
Efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in Asian participants with human immunodeficiency virus 1 infection: A sub-analysis of phase 3 clinical trialsYeon-Sook Kim, Shinichi Oka, Ploenchan Chetchotisakd, et al.
JAMA|March 1, 2024
HIV Preexposure Prophylaxis With Emtricitabine and Tenofovir Disoproxil Fumarate Among Cisgender WomenJeanne Marrazzo, Li Tao, Marissa Becker, et al.
Addictive Behaviors|January 3, 2012
Injection behaviors among injection drug users in treatment: the role of hepatitis C awarenessP Todd Korthuis, Daniel J Feaster, Zoilyn L Gomez, et al.
The Lancet. HIV|February 25, 2018
Tenofovir alafenamide plus emtricitabine versus abacavir plus lamivudine for treatment of virologically suppressed HIV-1-infected adults: a randomised, double-blind, active-controlled, non-inferiority phase 3 trialAlan Winston, Frank A Post, Edwin DeJesus, et al.
The Lancet. HIV|December 18, 2018
Safety of elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in HIV-1-infected adults with end-stage renal disease on chronic haemodialysis: an open-label, single-arm, multicentre, phase 3b trialJoseph J Eron, Jean-Daniel Lelievre, Robert Kalayjian, et al.
Pageof 7

Showing results (31-40 of 61) with videos related to

Sort By:
Pageof 7
Prevention Science : the Official Journal of the Society for Prevention Research|February 16, 2013
A roadmap for adapting an evidence-based HIV prevention intervention: personal cognitive counseling (PCC) for episodic substance-using men who have sex with menKelly R Knight, Moupali Das, Erin DeMicco, et al.
Clinical Pharmacology and Therapeutics|December 23, 2022
Facilitating Next-Generation Pre-Exposure Prophylaxis Clinical Trials Using HIV Recent Infection Assays: A Consensus Statement from the Forum HIV Prevention Trial Design ProjectNeil Parkin, Fei Gao, Eduard Grebe, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|March 11, 2017
Brief Report: Randomized, Double-Blind Comparison of Tenofovir Alafenamide (TAF) vs Tenofovir Disoproxil Fumarate (TDF), Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine (E/C/F) for Initial HIV-1 Treatment: Week 144 ResultsJosé R Arribas, Melanie Thompson, Paul E Sax, et al.
Transgender Health|February 5, 2024
Gender Affirming Hormones Do Not Affect the Exposure and Efficacy of F/TDF or F/TAF for HIV Preexposure Prophylaxis: A Subgroup Analysis from the DISCOVER TrialMichelle S Cespedes, Moupali Das, Jenna Yager, et al.
Ebiomedicine|October 16, 2016
Equivalent Decline in Inflammation Markers with Tenofovir Disoproxil Fumarate vs. Tenofovir AlafenamideNicholas T Funderburg, Grace A McComsey, Manjusha Kulkarni, et al.
HIV Research & Clinical Practice|July 16, 2019
Efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in Asian participants with human immunodeficiency virus 1 infection: A sub-analysis of phase 3 clinical trialsYeon-Sook Kim, Shinichi Oka, Ploenchan Chetchotisakd, et al.
JAMA|March 1, 2024
HIV Preexposure Prophylaxis With Emtricitabine and Tenofovir Disoproxil Fumarate Among Cisgender WomenJeanne Marrazzo, Li Tao, Marissa Becker, et al.
Addictive Behaviors|January 3, 2012
Injection behaviors among injection drug users in treatment: the role of hepatitis C awarenessP Todd Korthuis, Daniel J Feaster, Zoilyn L Gomez, et al.
The Lancet. HIV|February 25, 2018
Tenofovir alafenamide plus emtricitabine versus abacavir plus lamivudine for treatment of virologically suppressed HIV-1-infected adults: a randomised, double-blind, active-controlled, non-inferiority phase 3 trialAlan Winston, Frank A Post, Edwin DeJesus, et al.
The Lancet. HIV|December 18, 2018
Safety of elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in HIV-1-infected adults with end-stage renal disease on chronic haemodialysis: an open-label, single-arm, multicentre, phase 3b trialJoseph J Eron, Jean-Daniel Lelievre, Robert Kalayjian, et al.
Pageof 7